PROMOMED GROUP started the development of a new generation antibiotic

Promomed 14 April 2021
The launch of the pilot-industrial series of the innovative drug was attended by the Plenipotentiary Representative of the President of Russia in the Volga Federal District Igor Komarov and Acting Head of the Republic of Mordovia Artem Zdunov.

In the presence of Igor Komarov and Artem Zdunov, during a visit to the Saransk Biokhimik plant (member of the PROMOMED GROUP), the initial procedure for creating active pharmaceutical substances (AFS) for the production of an innovative new generation antibiotic was carried out. In the future, the drug will be used in the treatment of severe diseases. The large-scale production will begin next year. «Development of a biotechnological product is a creative process. It involves living organisms whose behavior is not always predictable, and it takes some time,» said Dmitry Zemskov, Executive Director of Biokhimik JSC. «Work on the development of the so-called reserve antibiotic has started. After testing the technology of industrial production of the drug, the plant will proceed to serial production.»

The medicine will be available for inpatient setting in the form of lyophilizate for intramuscular and intravenous administration. The technological capacities of the pharmaceutical enterprise already allow it to be produced in the volumes necessary to meet all the needs of Russian medical institutions.

At Biokhimik plant, one of the largest pharmaceutical production sites in Russia, Igor Komarov and Artem Zdunov also inspected the workshop for the production of active pharmaceutical substances for the production of antibiotics and a research and production site where promising drugs are being developed. Chairman of the Board of Directors of Promomed Group Petr Bely told the guests about the transition to full-cycle production and the innovative developments that the company is conducting, achieving improved efficiency and safety profile of its drugs.

Promomed Group is the leader of the national pharmaceutical industry in the production of drugs to control infections, with its own research and production site Biokhimik JSC. The company has 5 workshops specializing in the production of tablets and capsules, ointments and gels, solutions in ampoules. In total, there are more than 150 drug names in the production line of the plant, and about 170 more are under development.